CN117581990A - Baicalin composition for improving endurance and preparation process thereof - Google Patents
Baicalin composition for improving endurance and preparation process thereof Download PDFInfo
- Publication number
- CN117581990A CN117581990A CN202311835919.8A CN202311835919A CN117581990A CN 117581990 A CN117581990 A CN 117581990A CN 202311835919 A CN202311835919 A CN 202311835919A CN 117581990 A CN117581990 A CN 117581990A
- Authority
- CN
- China
- Prior art keywords
- parts
- baicalin
- ginseng
- vitamin
- mass
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- IPQKDIRUZHOIOM-UHFFFAOYSA-N Oroxin A Natural products OC1C(O)C(O)C(CO)OC1OC(C(=C1O)O)=CC2=C1C(=O)C=C(C=1C=CC=CC=1)O2 IPQKDIRUZHOIOM-UHFFFAOYSA-N 0.000 title claims abstract description 73
- IKIIZLYTISPENI-ZFORQUDYSA-N baicalin Chemical compound O1[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1OC(C(=C1O)O)=CC2=C1C(=O)C=C(C=1C=CC=CC=1)O2 IKIIZLYTISPENI-ZFORQUDYSA-N 0.000 title claims abstract description 73
- 229960003321 baicalin Drugs 0.000 title claims abstract description 73
- AQHDANHUMGXSJZ-UHFFFAOYSA-N baicalin Natural products OC1C(O)C(C(O)CO)OC1OC(C(=C1O)O)=CC2=C1C(=O)C=C(C=1C=CC=CC=1)O2 AQHDANHUMGXSJZ-UHFFFAOYSA-N 0.000 title claims abstract description 73
- 239000000203 mixture Substances 0.000 title claims abstract description 67
- 238000002360 preparation method Methods 0.000 title claims abstract description 24
- 241000208340 Araliaceae Species 0.000 claims abstract description 57
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 claims abstract description 57
- 235000003140 Panax quinquefolius Nutrition 0.000 claims abstract description 57
- 235000008434 ginseng Nutrition 0.000 claims abstract description 57
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 claims abstract description 44
- XOAAWQZATWQOTB-UHFFFAOYSA-N taurine Chemical compound NCCS(O)(=O)=O XOAAWQZATWQOTB-UHFFFAOYSA-N 0.000 claims abstract description 44
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims abstract description 42
- PHIQHXFUZVPYII-ZCFIWIBFSA-N (R)-carnitine Chemical compound C[N+](C)(C)C[C@H](O)CC([O-])=O PHIQHXFUZVPYII-ZCFIWIBFSA-N 0.000 claims abstract description 24
- AUNGANRZJHBGPY-UHFFFAOYSA-N D-Lyxoflavin Natural products OCC(O)C(O)C(O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-UHFFFAOYSA-N 0.000 claims abstract description 23
- AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 claims abstract description 23
- 229930003471 Vitamin B2 Natural products 0.000 claims abstract description 23
- 239000000395 magnesium oxide Substances 0.000 claims abstract description 23
- CPLXHLVBOLITMK-UHFFFAOYSA-N magnesium oxide Inorganic materials [Mg]=O CPLXHLVBOLITMK-UHFFFAOYSA-N 0.000 claims abstract description 23
- AXZKOIWUVFPNLO-UHFFFAOYSA-N magnesium;oxygen(2-) Chemical compound [O-2].[Mg+2] AXZKOIWUVFPNLO-UHFFFAOYSA-N 0.000 claims abstract description 23
- 239000000463 material Substances 0.000 claims abstract description 23
- 229960002477 riboflavin Drugs 0.000 claims abstract description 23
- 235000019164 vitamin B2 Nutrition 0.000 claims abstract description 23
- 239000011716 vitamin B2 Substances 0.000 claims abstract description 23
- 239000001103 potassium chloride Substances 0.000 claims abstract description 22
- 235000011164 potassium chloride Nutrition 0.000 claims abstract description 22
- 229960003080 taurine Drugs 0.000 claims abstract description 22
- 229930003451 Vitamin B1 Natural products 0.000 claims abstract description 21
- 239000011780 sodium chloride Substances 0.000 claims abstract description 21
- 229960003495 thiamine Drugs 0.000 claims abstract description 21
- DPJRMOMPQZCRJU-UHFFFAOYSA-M thiamine hydrochloride Chemical compound Cl.[Cl-].CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N DPJRMOMPQZCRJU-UHFFFAOYSA-M 0.000 claims abstract description 21
- 235000010374 vitamin B1 Nutrition 0.000 claims abstract description 21
- 239000011691 vitamin B1 Substances 0.000 claims abstract description 21
- 241000234276 Curculigo Species 0.000 claims abstract description 19
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 26
- 229960000869 magnesium oxide Drugs 0.000 claims description 22
- 235000012245 magnesium oxide Nutrition 0.000 claims description 22
- 239000004386 Erythritol Substances 0.000 claims description 20
- UNXHWFMMPAWVPI-UHFFFAOYSA-N Erythritol Natural products OCC(O)C(O)CO UNXHWFMMPAWVPI-UHFFFAOYSA-N 0.000 claims description 20
- UNXHWFMMPAWVPI-ZXZARUISSA-N erythritol Chemical compound OC[C@H](O)[C@H](O)CO UNXHWFMMPAWVPI-ZXZARUISSA-N 0.000 claims description 20
- 229940009714 erythritol Drugs 0.000 claims description 20
- 235000019414 erythritol Nutrition 0.000 claims description 20
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 claims description 18
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 claims description 18
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 claims description 18
- 229960003943 hypromellose Drugs 0.000 claims description 18
- 235000002639 sodium chloride Nutrition 0.000 claims description 17
- 238000000034 method Methods 0.000 claims description 11
- 238000001035 drying Methods 0.000 claims description 10
- 239000002245 particle Substances 0.000 claims description 7
- 239000002994 raw material Substances 0.000 claims description 7
- -1 rhizoma Curculiginis Chemical compound 0.000 claims description 7
- 238000002156 mixing Methods 0.000 claims description 6
- 229960002816 potassium chloride Drugs 0.000 claims description 6
- 229960002668 sodium chloride Drugs 0.000 claims description 6
- 238000000227 grinding Methods 0.000 claims description 5
- 230000008569 process Effects 0.000 claims description 5
- 235000020710 ginseng extract Nutrition 0.000 claims description 4
- 238000010298 pulverizing process Methods 0.000 claims description 4
- 239000008188 pellet Substances 0.000 claims description 3
- 235000009508 confectionery Nutrition 0.000 claims description 2
- 238000000605 extraction Methods 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 claims description 2
- 239000002671 adjuvant Substances 0.000 claims 1
- 235000016709 nutrition Nutrition 0.000 abstract description 9
- 230000035764 nutrition Effects 0.000 abstract description 8
- 239000013589 supplement Substances 0.000 abstract description 8
- 235000013305 food Nutrition 0.000 abstract description 2
- 230000000694 effects Effects 0.000 description 30
- 238000012360 testing method Methods 0.000 description 26
- 241000699670 Mus sp. Species 0.000 description 22
- 210000004369 blood Anatomy 0.000 description 22
- 239000008280 blood Substances 0.000 description 22
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 22
- 239000013642 negative control Substances 0.000 description 20
- 230000009182 swimming Effects 0.000 description 20
- 230000000052 comparative effect Effects 0.000 description 15
- 210000004185 liver Anatomy 0.000 description 15
- 229920002527 Glycogen Polymers 0.000 description 11
- 229940096919 glycogen Drugs 0.000 description 11
- 239000004310 lactic acid Substances 0.000 description 11
- 235000014655 lactic acid Nutrition 0.000 description 11
- 230000004060 metabolic process Effects 0.000 description 11
- 210000002966 serum Anatomy 0.000 description 10
- 241000699666 Mus <mouse, genus> Species 0.000 description 8
- PNNCWTXUWKENPE-UHFFFAOYSA-N [N].NC(N)=O Chemical compound [N].NC(N)=O PNNCWTXUWKENPE-UHFFFAOYSA-N 0.000 description 8
- 230000001976 improved effect Effects 0.000 description 8
- 241001465754 Metazoa Species 0.000 description 7
- 239000004480 active ingredient Substances 0.000 description 6
- 238000011161 development Methods 0.000 description 6
- 230000018109 developmental process Effects 0.000 description 6
- 230000012010 growth Effects 0.000 description 6
- 230000001737 promoting effect Effects 0.000 description 6
- 230000008901 benefit Effects 0.000 description 5
- 230000002708 enhancing effect Effects 0.000 description 5
- SMDOOINVMJSDPS-UHFFFAOYSA-N Astragaloside Natural products C1=C(O)C(OC)=CC(C2=C(C(=O)C3=C(O)C=C(O)C=C3O2)OC2C(C(OC3C(C(O)C(O)C(CO)O3)O)C(O)C(CO)O2)O)=C1 SMDOOINVMJSDPS-UHFFFAOYSA-N 0.000 description 4
- 102000019197 Superoxide Dismutase Human genes 0.000 description 4
- 108010012715 Superoxide dismutase Proteins 0.000 description 4
- 238000000540 analysis of variance Methods 0.000 description 4
- QMNWISYXSJWHRY-XWJCTJPOSA-N astragaloside Chemical compound O1[C@H](C(C)(O)C)CC[C@]1(C)[C@@H]1[C@@]2(C)CC[C@]34C[C@]4(CC[C@H](O[C@H]4[C@@H]([C@@H](O)[C@H](O)CO4)O)C4(C)C)C4[C@@H](O[C@H]4[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O4)O)CC3[C@]2(C)C[C@@H]1O QMNWISYXSJWHRY-XWJCTJPOSA-N 0.000 description 4
- 230000009286 beneficial effect Effects 0.000 description 4
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 4
- 230000001965 increasing effect Effects 0.000 description 4
- 229960001518 levocarnitine Drugs 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- 230000002633 protecting effect Effects 0.000 description 4
- 102000004190 Enzymes Human genes 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 3
- 108090001030 Lipoproteins Proteins 0.000 description 3
- 102000004895 Lipoproteins Human genes 0.000 description 3
- GAMYVSCDDLXAQW-AOIWZFSPSA-N Thermopsosid Natural products O(C)c1c(O)ccc(C=2Oc3c(c(O)cc(O[C@H]4[C@H](O)[C@@H](O)[C@H](O)[C@H](CO)O4)c3)C(=O)C=2)c1 GAMYVSCDDLXAQW-AOIWZFSPSA-N 0.000 description 3
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 3
- 239000004202 carbamide Substances 0.000 description 3
- 239000003153 chemical reaction reagent Substances 0.000 description 3
- 239000012153 distilled water Substances 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 229930003944 flavone Natural products 0.000 description 3
- 150000002212 flavone derivatives Chemical class 0.000 description 3
- 235000011949 flavones Nutrition 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 150000004676 glycans Chemical class 0.000 description 3
- 230000036039 immunity Effects 0.000 description 3
- 150000002632 lipids Chemical class 0.000 description 3
- 230000033001 locomotion Effects 0.000 description 3
- 238000005259 measurement Methods 0.000 description 3
- 229920001282 polysaccharide Polymers 0.000 description 3
- 239000005017 polysaccharide Substances 0.000 description 3
- 230000001105 regulatory effect Effects 0.000 description 3
- 239000007858 starting material Substances 0.000 description 3
- 230000001502 supplementing effect Effects 0.000 description 3
- 230000002195 synergetic effect Effects 0.000 description 3
- 239000003053 toxin Substances 0.000 description 3
- 231100000765 toxin Toxicity 0.000 description 3
- 108700012359 toxins Proteins 0.000 description 3
- VHBFFQKBGNRLFZ-UHFFFAOYSA-N vitamin p Natural products O1C2=CC=CC=C2C(=O)C=C1C1=CC=CC=C1 VHBFFQKBGNRLFZ-UHFFFAOYSA-N 0.000 description 3
- 206010002660 Anoxia Diseases 0.000 description 2
- 241000976983 Anoxia Species 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 102000016938 Catalase Human genes 0.000 description 2
- 108010053835 Catalase Proteins 0.000 description 2
- 206010021143 Hypoxia Diseases 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 2
- WSMYVTOQOOLQHP-UHFFFAOYSA-N Malondialdehyde Chemical compound O=CCC=O WSMYVTOQOOLQHP-UHFFFAOYSA-N 0.000 description 2
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 2
- DJSISFGPUUYILV-UHFFFAOYSA-N UNPD161792 Natural products O1C(C(O)=O)C(O)C(O)C(O)C1OC(C(=C1O)O)=CC2=C1C(=O)C=C(C=1C=CC(O)=CC=1)O2 DJSISFGPUUYILV-UHFFFAOYSA-N 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 230000007953 anoxia Effects 0.000 description 2
- 230000003110 anti-inflammatory effect Effects 0.000 description 2
- 230000003078 antioxidant effect Effects 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 210000000988 bone and bone Anatomy 0.000 description 2
- NPLTVGMLNDMOQE-UHFFFAOYSA-N carthamidin Natural products C1=CC(O)=CC=C1C1OC2=CC(O)=C(O)C(O)=C2C(=O)C1 NPLTVGMLNDMOQE-UHFFFAOYSA-N 0.000 description 2
- 210000003169 central nervous system Anatomy 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 230000034994 death Effects 0.000 description 2
- 210000002249 digestive system Anatomy 0.000 description 2
- BTCSSZJGUNDROE-UHFFFAOYSA-N gamma-aminobutyric acid Chemical compound NCCCC(O)=O BTCSSZJGUNDROE-UHFFFAOYSA-N 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 229940118019 malondialdehyde Drugs 0.000 description 2
- 210000003205 muscle Anatomy 0.000 description 2
- 210000000653 nervous system Anatomy 0.000 description 2
- LXNHXLLTXMVWPM-UHFFFAOYSA-N pyridoxine Chemical compound CC1=NC=C(CO)C(CO)=C1O LXNHXLLTXMVWPM-UHFFFAOYSA-N 0.000 description 2
- 239000001397 quillaja saponaria molina bark Substances 0.000 description 2
- 229930182490 saponin Natural products 0.000 description 2
- 150000007949 saponins Chemical class 0.000 description 2
- DJSISFGPUUYILV-ZFORQUDYSA-N scutellarin Chemical compound O1[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1OC(C(=C1O)O)=CC2=C1C(=O)C=C(C=1C=CC(O)=CC=1)O2 DJSISFGPUUYILV-ZFORQUDYSA-N 0.000 description 2
- 229930190376 scutellarin Natural products 0.000 description 2
- 238000005728 strengthening Methods 0.000 description 2
- 235000019156 vitamin B Nutrition 0.000 description 2
- 239000011720 vitamin B Substances 0.000 description 2
- OGNSCSPNOLGXSM-UHFFFAOYSA-N (+/-)-DABA Natural products NCCC(N)C(O)=O OGNSCSPNOLGXSM-UHFFFAOYSA-N 0.000 description 1
- 206010000087 Abdominal pain upper Diseases 0.000 description 1
- 208000019901 Anxiety disease Diseases 0.000 description 1
- FXNFHKRTJBSTCS-UHFFFAOYSA-N Baicalein Natural products C=1C(=O)C=2C(O)=C(O)C(O)=CC=2OC=1C1=CC=CC=C1 FXNFHKRTJBSTCS-UHFFFAOYSA-N 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 206010065559 Cerebral arteriosclerosis Diseases 0.000 description 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
- 244000084791 Curculigo orchioides Species 0.000 description 1
- 208000035240 Disease Resistance Diseases 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 238000012449 Kunming mouse Methods 0.000 description 1
- 108010013563 Lipoprotein Lipase Proteins 0.000 description 1
- 102100022119 Lipoprotein lipase Human genes 0.000 description 1
- 241001417092 Macrouridae Species 0.000 description 1
- 208000001132 Osteoporosis Diseases 0.000 description 1
- 208000002193 Pain Diseases 0.000 description 1
- 235000009233 Stachytarpheta cayennensis Nutrition 0.000 description 1
- 208000007536 Thrombosis Diseases 0.000 description 1
- 229930003270 Vitamin B Natural products 0.000 description 1
- 241000276425 Xiphophorus maculatus Species 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000003266 anti-allergic effect Effects 0.000 description 1
- 230000002686 anti-diuretic effect Effects 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 230000000767 anti-ulcer Effects 0.000 description 1
- 229940124538 antidiuretic agent Drugs 0.000 description 1
- 239000003160 antidiuretic agent Substances 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 230000036506 anxiety Effects 0.000 description 1
- 230000036528 appetite Effects 0.000 description 1
- 235000019789 appetite Nutrition 0.000 description 1
- QMNWISYXSJWHRY-YLNUDOOFSA-N astragaloside IV Chemical compound O1[C@H](C(C)(O)C)CC[C@]1(C)[C@@H]1[C@@]2(C)CC[C@]34C[C@]4(CC[C@H](O[C@H]4[C@@H]([C@@H](O)[C@H](O)CO4)O)C4(C)C)[C@H]4[C@@H](O[C@H]4[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O4)O)C[C@H]3[C@]2(C)C[C@@H]1O QMNWISYXSJWHRY-YLNUDOOFSA-N 0.000 description 1
- QMNWISYXSJWHRY-BCBPIKMJSA-N astragaloside IV Natural products CC(C)(O)[C@@H]1CC[C@@](C)(O1)[C@H]2[C@@H](O)C[C@@]3(C)[C@@H]4C[C@H](O[C@@H]5O[C@H](CO)[C@H](O)[C@@H](O)[C@H]5O)[C@H]6C(C)(C)[C@H](CC[C@@]67C[C@@]47CC[C@]23C)O[C@@H]8OC[C@@H](O)[C@H](O)[C@H]8O QMNWISYXSJWHRY-BCBPIKMJSA-N 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- UDFLTIRFTXWNJO-UHFFFAOYSA-N baicalein Chemical group O1C2=CC(=O)C(O)=C(O)C2=C(O)C=C1C1=CC=CC=C1 UDFLTIRFTXWNJO-UHFFFAOYSA-N 0.000 description 1
- 229940015301 baicalein Drugs 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 210000005252 bulbus oculi Anatomy 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 230000001914 calming effect Effects 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 230000005189 cardiac health Effects 0.000 description 1
- 210000000748 cardiovascular system Anatomy 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 208000026106 cerebrovascular disease Diseases 0.000 description 1
- 239000000460 chlorine Substances 0.000 description 1
- 229910052801 chlorine Inorganic materials 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 230000009194 climbing Effects 0.000 description 1
- 239000005515 coenzyme Substances 0.000 description 1
- 230000008602 contraction Effects 0.000 description 1
- PFKIBRPYVNVMRU-UHFFFAOYSA-N cyclosieversioside F Natural products CC(C)(O)C1COC(C)(C1)C2C(O)CC3(C)C4CC(OC5OC(CO)C(O)C(O)C5O)C6C(C)(C)C(CCC67CC47CCC23C)OC8OCC(O)C(O)C8O PFKIBRPYVNVMRU-UHFFFAOYSA-N 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 201000006549 dyspepsia Diseases 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- 230000008451 emotion Effects 0.000 description 1
- 230000002996 emotional effect Effects 0.000 description 1
- 230000037149 energy metabolism Effects 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- 230000037080 exercise endurance Effects 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 229930003935 flavonoid Natural products 0.000 description 1
- 150000002215 flavonoids Chemical class 0.000 description 1
- 235000017173 flavonoids Nutrition 0.000 description 1
- 235000012041 food component Nutrition 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 229960003692 gamma aminobutyric acid Drugs 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 230000005176 gastrointestinal motility Effects 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 239000004519 grease Substances 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000004217 heart function Effects 0.000 description 1
- 230000011132 hemopoiesis Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 150000002484 inorganic compounds Chemical class 0.000 description 1
- 229910010272 inorganic material Inorganic materials 0.000 description 1
- 201000005851 intracranial arteriosclerosis Diseases 0.000 description 1
- 230000037356 lipid metabolism Effects 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 230000004199 lung function Effects 0.000 description 1
- 230000036649 mental concentration Effects 0.000 description 1
- 230000003340 mental effect Effects 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 230000037345 metabolism of vitamins Effects 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- 230000002107 myocardial effect Effects 0.000 description 1
- 230000010016 myocardial function Effects 0.000 description 1
- 208000031225 myocardial ischemia Diseases 0.000 description 1
- 210000004165 myocardium Anatomy 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 208000004296 neuralgia Diseases 0.000 description 1
- 239000002858 neurotransmitter agent Substances 0.000 description 1
- 235000001968 nicotinic acid Nutrition 0.000 description 1
- 239000011664 nicotinic acid Substances 0.000 description 1
- 229960003512 nicotinic acid Drugs 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 235000020733 paullinia cupana extract Nutrition 0.000 description 1
- 230000008855 peristalsis Effects 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 238000010926 purge Methods 0.000 description 1
- RADKZDMFGJYCBB-UHFFFAOYSA-N pyridoxal hydrochloride Natural products CC1=NC=C(CO)C(C=O)=C1O RADKZDMFGJYCBB-UHFFFAOYSA-N 0.000 description 1
- 230000004223 radioprotective effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 210000002345 respiratory system Anatomy 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 230000000284 resting effect Effects 0.000 description 1
- 238000007493 shaping process Methods 0.000 description 1
- 230000035939 shock Effects 0.000 description 1
- 230000003860 sleep quality Effects 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 239000010902 straw Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 230000009469 supplementation Effects 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 239000003440 toxic substance Substances 0.000 description 1
- 239000011573 trace mineral Substances 0.000 description 1
- 235000013619 trace mineral Nutrition 0.000 description 1
- 238000000870 ultraviolet spectroscopy Methods 0.000 description 1
- 238000012795 verification Methods 0.000 description 1
- 235000019158 vitamin B6 Nutrition 0.000 description 1
- 239000011726 vitamin B6 Substances 0.000 description 1
- 229940011671 vitamin b6 Drugs 0.000 description 1
- 239000000341 volatile oil Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/15—Vitamins
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/16—Inorganic salts, minerals or trace elements
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/17—Amino acids, peptides or proteins
- A23L33/175—Amino acids
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Mycology (AREA)
- Health & Medical Sciences (AREA)
- Nutrition Science (AREA)
- Engineering & Computer Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Botany (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Inorganic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention belongs to the technical field of sports foods, and relates to a baicalin composition for improving endurance and a preparation process thereof, wherein the baicalin composition for improving endurance comprises the following main materials in parts by mass: ginseng, vitamin B1, vitamin B2, L-carnitine, taurine, baicalin, curculigo rhizome, sodium chloride, potassium chloride and magnesium oxide. The baicalin composition prepared by the invention improves the tolerance of organisms, provides nutrition for the organisms, supplements a large amount of energy consumed by exercise and maintains physical strength for a long time.
Description
Technical Field
The invention belongs to the technical field of sports foods, and relates to a baicalin composition for improving endurance and a preparation process thereof.
Background
In common telephone, life lies in exercise, and proper amount of exercise is beneficial to health, so that people are more mental, exercise is beneficial to growth of bones and muscles of the human body, heart and lung functions are enhanced, functional conditions of a blood circulation system, a respiratory system and a digestive system are improved, growth and development of the human body are facilitated, disease resistance is improved, and adaptability of organisms is enhanced. Therefore, more and more people participate in climbing mountain, riding, swimming and other sports. But often consume a lot of energy during exercise, and thus require energy and nutrition to support the body for better participation in the exercise.
For example, patent document CN111557402a is a pre-exercise starter and a preparation process thereof, the pre-exercise starter comprising the following ingredients: the pre-exercise starter can play a role in 10 minutes from the aspects of absorption speed and overall effect, has strong body feeling, has the advantages of a common nitrogen pump, can improve metabolism and improve mental concentration of people; the L-carnitine component contained in the oil can also burn grease with high efficiency; however, due to the use of guarana extract, the compound has quick response and stimulation to human bodies, but has short duration, cannot exert great efficacy, causes the supplementation of nutrition and energy, has short duration of endurance, and cannot meet the long-time exercise requirement.
Disclosure of Invention
Aiming at the technical problems that the endurance duration is short and the long-time exercise requirement cannot be met, the invention provides a baicalin composition for improving endurance and a preparation process thereof.
The invention adopts the baicalin composition prepared from ginseng, vitamin B1, vitamin B2, L-carnitine, taurine, baicalin, curculigo rhizome, sodium chloride, potassium chloride and magnesium oxide, improves the tolerance of the organism, provides nutrition for the organism, supplements a large amount of energy consumed by exercise and maintains the physical strength for a long time.
In order to achieve the above purpose, the technical scheme adopted by the invention is as follows:
the baicalin composition for improving endurance comprises the following main materials in parts by mass:
80 to 780 parts of ginseng, 1 to 25 parts of vitamin B1, 1 to 25 parts of vitamin B2, 3 to 750 parts of L-carnitine, 20 to 860 parts of taurine, 5 to 300 parts of baicalin, 24 to 1600 parts of curculigo rhizome, 10 to 600 parts of sodium chloride, 10 to 600 parts of potassium chloride and 2 to 450 parts of magnesium oxide.
Further defined, the baicalin composition for improving endurance comprises the following main materials in parts by mass:
150 to 500 parts of ginseng, 1 to 10 parts of vitamin B1, 1 to 10 parts of vitamin B2, 10 to 500 parts of L-carnitine, 50 to 450 parts of taurine, 10 to 200 parts of baicalin, 80 to 900 parts of curculigo rhizome, 90 to 400 parts of sodium chloride, 90 to 400 parts of potassium chloride and 6 to 150 parts of magnesium oxide.
Further defined, the baicalin composition for improving endurance comprises the following main materials in parts by mass:
200 parts of ginseng, 1 part of vitamin B1, 1 part of vitamin B2, 100 parts of L-carnitine, 240 parts of taurine, 50 parts of baicalin, 500 parts of curculigo rhizome, 200 parts of sodium chloride, 200 parts of potassium chloride and 30 parts of magnesium oxide.
Further defined, the endurance-enhancing baicalin composition further comprises an auxiliary material, wherein the auxiliary material comprises erythritol and hypromellose; the mass parts of erythritol and hypromellose are respectively 70-700 parts and 10-400 parts.
Further defined, the erythritol and hypromellose are 200 to 400 parts and 50 to 200 parts by mass, respectively.
A preparation process of the baicalin composition for improving endurance comprises the following steps of:
1) Preparing corresponding raw materials according to the parts by mass;
2) Pulverizing the ginseng of step 1) into particles, and extracting, concentrating, drying and grinding to obtain ginseng extract;
3) Sequentially adding vitamin B1, vitamin B2, L-carnitine, taurine, baicalin, rhizoma Curculiginis, sodium chloride, potassium chloride, magnesium oxide, erythritol and hypromellose into the Ginseng radix extract in step 2), and mixing to obtain baicalin composition preparation.
Further defined, the extracting in the step 2) is: adding water into crushed ginseng particles, and decocting for 1 to 3 times at the temperature of between 95 and 110 ℃ for 0.5 to 3 hours each time; the mass of the added water is 5-12 times of that of the ginseng.
Further defined, when the decoction is performed for 3 times, the mass of water added for the first time is 12 times that of ginseng, and the decoction is performed for 3 hours; the mass of water added for the second time is 9 times of that of ginseng, and the ginseng is decocted for 2 hours; the third time of adding water is 5 times of the ginseng, and the mixture is decocted for 1 hour.
Further defined, in said step 2), the conditions for concentration are: 40-60 ℃; the drying conditions were: the temperature is 60-90 ℃ and the time is less than or equal to 12 hours.
Further defined, in the step 3), the candy is in a sheet form or a pellet form.
The beneficial effects of the invention are as follows:
1. the invention adopts the baicalin composition prepared from ginseng, vitamin B1, vitamin B2, L-carnitine, taurine, baicalin, curculigo rhizome, sodium chloride, potassium chloride and magnesium oxide, improves the tolerance of the organism, provides nutrition for the organism, supplements a large amount of energy consumed by exercise, and maintains physical strength for a long time, thereby participating in exercise better.
2. The baicalin composition provided by the invention has the advantages that the components are synergistic, the activity of lipoprotein enzyme is improved, the fat metabolism rate is increased, the products and toxins in the organism are rapidly discharged, and the normal activity of the organism is maintained.
3. The ginseng is extracted by adopting a stewing method, and the content of active components in the ginseng is improved, so that the tolerance of the organism is greatly improved, and the fat metabolism is promoted.
Detailed Description
The baicalin composition for improving endurance provided by the invention comprises the following main materials in parts by mass.
Ginseng: qi-tonifying medicine, ginseng can resist shock, strengthen heart, lower blood pressure, resist anoxia, protect cardiac muscle, improve haemorheology and resist thrombosis; has effects in exciting pituitary-adrenal cortex system, resisting stress, enhancing immunity, improving hematopoiesis, regulating balance of central nervous system excitation and inhibiting process, promoting learning and memory, and relieving fatigue; can regulate cholesterol metabolism, reduce blood lipid and blood glucose; it also has antiinflammatory, antiallergic, antidiuretic, antitumor, antiulcer, radioprotective, liver protecting, and antioxidant effects. The active ingredients of Ginseng radix include Ginseng radix polypeptide, ginseng radix polysaccharide, ginseng radix flavone, ginseng radix volatile oil, etc.; the active ingredients can activate lipoprotein lipase, remove excessive blood lipid and cholesterol, thereby achieving the purpose of reducing blood lipid, and has a certain effect on inhibiting cerebral arteriosclerosis. Can reduce myocardial ischemia, reduce coronary resistance, and protect heart; also has certain body strengthening function.
Vitamin B1: can maintain normal sugar metabolism and functions of nervous and digestive systems; has effects of relieving fatigue, supplying energy to muscle, promoting fatigue factor decomposition, and enhancing physical strength; has effects in regulating sugar metabolism, accelerating gastrointestinal motility, promoting digestion, and especially acting on carbohydrate to improve appetite; has effects in maintaining heart health, and enhancing oxygen and nutrient utilization of heart; in addition, it also has effects of enhancing immunity, relieving neuralgia, promoting growth and development, promoting energy metabolism, and regulating emotion.
Vitamin B2: vitamin B2 is a B vitamin, is taken as coenzyme to participate in the metabolic process in vivo, and can promote the growth and development of organisms and maintain the integrity of cell membranes; vitamin B2 can participate in the metabolism of vitamin B6 and nicotinic acid, so that the vitamin B group coordinates with each other to play a role.
L-carnitine: the L-carnitine can release a large amount of energy, is particularly suitable for athletes to eat, can supplement a large amount of energy, and can prolong exercise time and enhance endurance; is suitable for athletes, and can rapidly relieve fatigue; l-carnitine is beneficial to promote fat catabolism.
Taurine: is an amino acid necessary for human body, participates in lipid metabolism of human body, and has multiple effects. Taurine has the main functions of protecting heart and increasing myocardial function; promoting the growth and development of human body and helping the growth and development of human bones.
Baicalin: is the chemical composition of baicalein, and has the effects of clearing heat and drying dampness; baicalin belongs to Chinese medicinal materials, and has effects of purging pathogenic fire and removing toxic substances; baicalin also has antioxidant, antiinflammatory, and blood sugar lowering effects; baicalin can also dilate blood vessel, prevent cardiovascular and cerebrovascular diseases, and enhance myocardial contraction ability.
Curculigo rhizome: is a deficiency-tonifying medicine, and is rhizome of Curculigo orchioides belonging to Curculigo. The rhizoma curculiginis has various pharmacological effects of enhancing immunity, resisting anoxia, strengthening heart, resisting inflammation, relieving pain, protecting liver, resisting osteoporosis and the like.
Sodium chloride: the compound is an inorganic compound, can supplement sodium element needed by human body, can supplement chlorine element needed by human body, can supplement nutrition for human body after proper eating, and can maintain nutrition balance in human body; it also has effects in supplementing blood volume, maintaining acid-base balance, maintaining osmotic pressure, maintaining electrolyte balance, and cleaning gastrointestinal tract.
Potassium chloride: can maintain the acid-base balance of the human body, keep the pH value of the human body within a certain range, and maintain the basic metabolism of organisms; potassium chloride can promote the development of the nervous system of human body, so that the nerves can be kept excited; can be used for treating fatigue and debilitation, and supplementing trace elements required by human body.
Magnesium oxide: magnesium oxide is a magnesium salt compound, and can play a role in calming after entering a human body, and can relieve the conditions of emotional stress, anxiety and the like; can release neurotransmitter of gamma-aminobutyric acid, regulate central nervous system, and relax body and brain, thereby improving sleep quality; because the magnesium oxide has a slight relief effect, the gastrointestinal peristalsis can be promoted, and symptoms such as gastralgia, fullness and the like caused by dyspepsia can be relieved. In addition, the product has effects of reducing weight, nourishing and supplementing calcium, and protecting cardiovascular system.
In order to ensure the tolerance effect of the baicalin composition, the baicalin composition for improving the tolerance comprises the following main materials in parts by mass: 80 to 780 parts of ginseng, 1 to 25 parts of vitamin B1, 1 to 25 parts of vitamin B2, 3 to 750 parts of L-carnitine, 20 to 860 parts of taurine, 5 to 300 parts of baicalin, 24 to 1600 parts of curculigo rhizome, 10 to 600 parts of sodium chloride, 10 to 600 parts of potassium chloride and 2 to 450 parts of magnesium oxide.
Preferably, the composition comprises the following main materials in parts by mass: 150 to 500 parts of ginseng, 1 to 10 parts of vitamin B1, 1 to 10 parts of vitamin B2, 10 to 500 parts of L-carnitine, 50 to 450 parts of taurine, 10 to 200 parts of baicalin, 80 to 900 parts of curculigo rhizome, 90 to 400 parts of sodium chloride, 90 to 400 parts of potassium chloride and 6 to 150 parts of magnesium oxide.
More preferably, the composition comprises the following main materials in parts by mass: 200 parts of ginseng, 1 part of vitamin B1, 1 part of vitamin B2, 100 parts of L-carnitine, 240 parts of taurine, 50 parts of baicalin, 500 parts of curculigo rhizome, 200 parts of sodium chloride, 200 parts of potassium chloride and 30 parts of magnesium oxide.
In order to improve the mouthfeel of the baicalin composition and facilitate shaping, the baicalin composition also comprises auxiliary materials, wherein the auxiliary materials comprise erythritol and hypromellose; the mass parts of erythritol and hypromellose are respectively 70-700 parts and 10-400 parts.
Preferably, the mass parts of erythritol and hypromellose are 200 to 400 parts and 50 to 200 parts, respectively.
Erythritol: is a bulk sweetener, is a four-carbon sugar alcohol, has good crystallinity, extremely low hygroscopicity, and low erythritol solubility, and can not absorb moisture even when the relative humidity is 90%; in addition, erythritol has the advantages of low sweetness and high stability.
Hypromellose: the semi-synthetic, inactive and viscoelastic polymer is often used as a lubricant for ophthalmology or used as an auxiliary material or excipient in oral medicines, has good crashability while being bonded, and has the performance of rapid dissolution, crashing and dispersion when being taken.
Preferably, the mass parts of erythritol and hypromellose are 200 to 400 parts and 50 to 200 parts, respectively.
More preferably, the mass parts of erythritol and hypromellose are 540 and 200, respectively.
The invention also provides a preparation process of the baicalin composition for improving endurance, which comprises the following steps.
1) Preparing corresponding raw materials according to the parts by mass;
2) Pulverizing the ginseng of step 1) into particles, and extracting, concentrating, drying and grinding to obtain ginseng extract;
3) Sequentially adding vitamin B1, vitamin B2, L-carnitine, taurine, baicalin, rhizoma Curculiginis, sodium chloride, potassium chloride, magnesium oxide, erythritol and hypromellose into the Ginseng radix extract in step 2), and mixing to obtain baicalin composition preparation.
The extraction process in the step 2) of the invention is as follows: adding water into crushed ginseng particles, and decocting for 1 to 3 times at the temperature of between 95 and 110 ℃ for 0.5 to 3 hours each time; the mass of the added water is 5-12 times of that of the ginseng.
In the invention, when the ginseng is decocted for 3 times, the mass of water added for the first time is 12 times that of ginseng, and the ginseng is decocted for 3 hours; the mass of water added for the second time is 9 times of that of ginseng, and the ginseng is decocted for 2 hours; the third time of adding water is 5 times of the ginseng, and the mixture is decocted for 1 hour.
In step 2) of the invention, the conditions for concentration are: 40-60 ℃; the drying conditions were: the temperature is 60-90 ℃ and the time is less than or equal to 12 hours.
In the step 3), the raw materials are mixed and then are further processed to prepare the platy or pellet baicalin composition preparation.
Technical advantages of the increased endurance baicalin composition provided by the present invention are illustrated by the following specific examples.
In the examples which follow, unless otherwise specified, the methods employed are conventional in the art,
such as mixing, drying, grinding, etc.
In the following examples, all materials, reagents, etc. used were purchased in the market.
Examples 1 to 8
The scutellarin composition for improving endurance provided in examples 1 to 8 comprises ginseng, vitamin B1, vitamin B2, l-carnitine, taurine, scutellarin, curculigo rhizome, sodium chloride, potassium chloride and magnesium oxide. The mass parts of the main materials are shown in table 1.
Table 1 mass parts of each main material in examples 1 to 8
Example 10
In order to improve the taste of the baicalin composition for improving the endurance and enable the baicalin composition to be easier to shape in the preparation and processing process, in the embodiment, auxiliary materials are further added into the baicalin composition, wherein the auxiliary materials comprise erythritol and hypromellose, and preferably, the mass parts of the erythritol and the hypromellose are 540 and 200 respectively.
The preparation process provided in this embodiment includes the following steps. 1) Preparing corresponding raw materials according to the mass part of the example 9;
2) Pulverizing the ginseng of step 1) into particles, and extracting, concentrating, drying and grinding to obtain ginseng extract;
in the step, the mixture is decocted for 3 times, the mass of water added for the first time is 12 times of that of ginseng, and the temperature is 110 ℃ and the decoction is carried out for 3 hours; the mass of water added for the second time is 9 times of that of ginseng, and the temperature is 105 ℃, and the ginseng is decocted for 2 hours; the third time of adding water is 5 times of the ginseng, and the temperature is 95 ℃ and the decoction is carried out for 1 hour. Filtering the three times of decoction, mixing filtrates, and concentrating at 60deg.C for 12 hr; finally, drying for 10 hours at 80 ℃ to obtain the human extract.
3) Sequentially adding vitamin B1, vitamin B2, L-carnitine, taurine, baicalin, rhizoma Curculiginis, sodium chloride, potassium chloride, magnesium oxide, erythritol and hypromellose into the Ginseng radix extract in step 2), mixing, tabletting, and making into tablet astragaloside composition.
Referring to the method of example 10, 8 sets of sheet-shaped baicalin composition preparations were prepared by using the mass parts of examples 1 to 8.
According to the astragaloside composition preparation obtained by the mass parts and the preparation process, the raw materials are synergistic, so that the content of active ingredients such as astragaloside IV is increased, the tolerance of an organism can be improved, a large amount of energy consumed by exercise is supplemented, and the physical strength is maintained for a long time; can also maximally promote the activity of lipoprotein enzyme, promote the fat metabolism rate of human body, rapidly discharge the products and toxins in the organism, and maintain the normal activity of the organism. The efficacy of the astragaloside composition of the present invention can be verified by the following test, while a comparative example is designed in the test verification, thereby illustrating the advantage of the astragaloside composition of the present invention in efficacy.
Comparative example 1
In this comparative example, a composition prepared from ginseng, vitamin B1, vitamin B2, L-carnitine, taurine, sodium chloride, potassium chloride, and magnesium oxide was used.
Comparative example 2
In this comparative example, a composition prepared from ginseng, vitamin B1, vitamin B2, l-carnitine, taurine, baicalin, sodium chloride, potassium chloride, and magnesium oxide was used.
Comparative example 3
In this comparative example, a composition prepared from ginseng, vitamin B1, vitamin B2, l-carnitine, taurine, curculigo rhizome, sodium chloride, potassium chloride, and magnesium oxide was used.
With reference to example 9 and further reference to the preparation process of example 10, 3 sets of sheet-like baicalin composition preparations were obtained by referring to the mass parts of the remaining respective raw materials in comparative examples 1 to 3.
The performance of the baicalin composition was verified by the following test.
Test 1
12 sets of baicalin composition preparations prepared in different mass parts of the above examples 1 to 9 and comparative examples 1 to 3 were taken.
The content of active ingredients of polysaccharide, saponin and flavone in the baicalin composition was analyzed. The analysis was performed using standard methods in the industry and the results are shown in table 2.
Table 2 active ingredients of baicalin compositions prepared in examples and comparative examples
| Polysaccharide | Saponin | Flavone | |
| Example 1 | 0.12％ | 0.09％ | 2.0％ |
| Example 2 | 0.22％ | 0.16％ | 3.1％ |
| Example 3 | 0.36％ | 0.28％ | 4.8％ |
| Example 4 | 0.65％ | 0.05％ | 6.8％ |
| Example 5 | 0.80％ | 0.06％ | 8.3％ |
| Example 6 | 0.90％ | 0.07％ | 0.14％ |
| Example 7 | 0.96％ | 0.06％ | 0.95％ |
| Example 8 | 2.12％ | 1.46％ | 2.27％ |
| Example 9 | 0.34％ | 1.42％ | 2.36％ |
| Comparative example 1 | 0.51％ | 0.035％ | 0.08％ |
| Comparative example 2 | 0.59％ | 0.044％ | 1.3％ |
| Comparative example 3 | 0.63％ | 0.057％ | 5.2％ |
As can be seen from Table 2, when baicalin and rhizoma Curculiginis are added at the same time, the increase of active ingredients can be promoted, the baicalin can promote the increase of superoxide dismutase (SOD) activity in human body, the content of Lipid Peroxide (LPO) is reduced, and further the exercise endurance is improved. The effective parts in the curculigo rhizome are flavonoid components, and researches show that the curculigo rhizome Mao Huangtong can improve the activities of superoxide dismutase (SOD) and Catalase (CAT) of a human body and reduce the level of Malondialdehyde (MDA) in the human body. The active components greatly improve the fatigue state of the human body and promote the metabolism of the human body.
Test 2
1. Materials and methods
1.1 sample
The baicalin composition preparation prepared in the mass part of example 9 is selected, the specification is 0.6 g/tablet, and the recommended amount of human body is 3 tablets each time and 2 times a day. The weight of the adult is calculated to be 60kg, and the folded dose is 0.06 g/kg.Bw.
1.2 test animals
Male Kunming mice (quality certificate No. 61001700001610, 61001700001639) were provided by the laboratory animal center of the university of Western An traffic medical college, and had a weight of 18-22g. Production license number: SCXK2012-003, spf stage. The laboratory animal house is a barrier system, the use license number is SYXK (Shaan 2012-006), the temperature is 20-25 ℃, and the relative humidity is 45-65%.
1.3 dose selection and formulation
Because the recommended daily dose of the human body is 0.06 g/kg.Bw, the dosage design is as follows: the test was carried out in three dosage groups (corresponding to 30, 20 and 10 times the recommended dose of human body) of 1.80 g/kg. Bw, 1.20 g/kg. Bw and 0.60 g/kg. Bw, and a negative (distilled water) control group was additionally provided. Sample preparation: 1.80g, 1.20g and 0.60g of samples are weighed, distilled water is added to 20mL respectively, and the samples are uniformly mixed.
1.4 instruments and reagents
1.4.1 major instrumentation, items:
swimming case, JD00-2 electronic balance, stopwatch, lead skin, T6-new century ultraviolet visible spectrophotometer, shenzhen Mairui BS-420 full-automatic biochemical analyzer, 10mL test tube with plug, thermometer, constant temperature water bath, centrifuge vortex oscillator, surgical instrument, microscale sampler, straw, scale centrifuge tube, etc.
1.4.2 reagents
Kit (produced by Nanjing Seisakusho technology Co., ltd.) and the like.
1.5 test methods
160 male mice with correct potential after pre-swimming are divided into four test groups of 40 mice each and randomly divided into 4 groups, and three dose groups and a negative control group are arranged in each test group. The number of test animals is 10, one group of load swimming tests, two groups of serum urea tests, three groups of liver glycogen tests and four groups of blood lactic acid tests. The corresponding dosage samples were given once daily orally at the doses indicated above, with a lavage volume of 20 mL/kg. Bw. The negative control group was given an equal volume of distilled water and was continuously gavaged for 30 days. Then, each index is measured respectively, and the method is as follows:
1.5.1 mouse load swimming test
After 3min from the last sample administration, the mice were placed in a swimming box for swimming with a water depth of 35cm and a water temperature of 25 ℃, and the roots of the rat tails were loaded with 5% of the weight of the lead skin. The time from the start of swimming to death was recorded for each group of mice, and as the mice' load swimming time, the results of each dose group were compared with the negative control group for analysis of variance. The death judgment standard is that the mice sink to the bottom of the swimming trunk and stop opening mouth to breathe. If the swimming time of the dosage group is obviously longer than that of the negative control group, and the difference is significant, the sample can be judged to have the effect of prolonging the load swimming time of the mice.
1.5.2 serum Urea Nitrogen determination
30 minutes after the last administration of the test sample, the test sample is swim for 90 minutes without load in water with the temperature of 30 ℃, the eyeball is pulled out to collect blood for 0.5mL after resting for 60 minutes after movement, centrifugation is carried out for 15 minutes at 2000r/min, serum urea nitrogen measurement is carried out by a full-automatic biochemical analyzer after serum is separated, and the results of each dosage group are compared with a negative control group for analysis of variance.
1.5.3 liver glycogen determination
Animals were sacrificed 30 minutes after the last administration of the test sample, livers were dissected and removed, liver glycogen was measured as required by the kit, and the results of each dose group were compared to the negative control group for analysis of variance. The liver glycogen determination is carried out by using a kit produced by Nanjing Seisakusho technology Co.
1.5.4 blood lactic acid assay
After the final administration of the test sample for 30 minutes, the mice were swim in water at 30 ℃ for 10 minutes without load, and were allowed to rest for 20 minutes before, after and after swimming, blood was collected three times (inner canthus blood collection) respectively to determine blood lactic acid content, and the results of each dose group were compared with the negative control group by using the area under the blood lactic acid curve at three time points as an index to conduct analysis of variance. The blood lactic acid measurement is carried out by using a kit produced by Nanjing Seisakusho technology Co.
2. Results
2.1 mouse load swimming test
As can be seen from table 2, the average swimming time of each dose group of mice is prolonged compared with the swimming time of the negative control group; the high dose group had significant differences (P < 0.01) compared to the negative control group. The results show that the sample has the effect of prolonging the load swimming time of the mice.
Table 2 results of the mouse load swim test
| Group (g/kg Bw) | Animal number (only) | Swimming time (min) | P value |
| 1.8 | 10 | 34.1±17.0 | 0.001** |
| 1.2 | 10 | 27.9±8.0 | 0.120 |
| 0.6 | 10 | 22.7±7.1 | 0.940 |
| Negative control group | 10 | 21.2±7.2 |
Note that: compared to the negative control group, P <0.01 is indicated.
2.2 mouse serum Urea Nitrogen assay
As can be seen from table 3, the serum urea content of each dose group was significantly lower than that of the negative control group; the serum urea nitrogen content of the mice in the high group was significantly different (P < 0.05) compared with the negative control group. The results show that the test sample has obvious effect on the generation of urea of the fatigued mice.
TABLE 3 Effect of serum Urea Nitrogen content in mice
| Group (g/kg Bw) | Animal number (only) | Urea nitrogen (mmol/L) | P value |
| 1.8 | 10 | 8.00±1.03 | 0.034* |
| 1.2 | 10 | 8.67±1.71 | 0.208 |
| 0.6 | 10 | 8.38±2.20 | 0.102 |
| Negative control group | 10 | 10.03±1.79 |
Note that: compared to the negative control group, P <0.05 is indicated.
2.3 mouse liver glycogen determination
As can be seen from Table 4, the liver glycogen of each dosage group is higher than that of the negative control group, which indicates that the baicalin composition provided by the invention can increase the reserve amount of the liver glycogen of mice.
TABLE 4 Effect of liver glycogen content in mice
| Group (g/kg Bw) | Animal number (only) | Liver glycogen (mg/100 g liver) |
| 1.8 | 10 | 2254.6±292.0 |
| 1.2 | 10 | 2241.2±217.8 |
| 0.6 | 10 | 2124.5±226.3 |
| Negative control group | 10 | 2010.9±192.9 |
2.4 determination of lactic acid in blood of mice
As can be seen from the results in table 5, the area under the blood lactic acid curve was smaller for each dose group of mice at three time points than for the negative control group; in addition, the high dose has significant variability (P < 0.01) compared to the negative control group. The results show that the tested sample has the effect of reducing the area under the blood lactic acid curve of the mice after exercise.
TABLE 5 influence of blood lactic acid content before and after movement in mice
Note that: compared to the negative control group, P <0.05 is indicated. The blood lactate content in the table and the area under the blood lactate curve at three time points are all average values.
From the above analysis of the results: the high-dose group can obviously prolong the load swimming time of the mice, and the high-dose group can reduce the serum urea nitrogen content of the mice; each dosage group can increase the reserve quantity of liver glycogen of mice, and each dosage group can obviously reduce the area under the blood lactic acid curve. Comprehensive judgment, the baicalin composition obtained in example 9 can enhance the endurance and physical strength of human bodies and greatly relieve the fatigue feeling caused by sports.
Test 3
For the nutritional compositions provided in examples 1 to 8 and comparative examples 1 to 3, a mouse model test was performed in accordance with the above-described method using a high dose, and the mouse weight-bearing swimming time, the mouse serum urea nitrogen content, the mouse liver glycogen storage amount, and the area under the blood lactic acid curve were measured, respectively, and the measurement results are shown in table 6.
Table 6 comparison of test results of examples and comparative examples
As can be seen from the comparison of Table 6, the baicalin composition provided by the invention has obvious effect of improving endurance, and the addition of baicalin and curculigo rhizome has synergistic promotion effect on improving endurance, and the endurance time is enhanced.
In conclusion, the baicalin composition provided by the invention can prolong the endurance time and maintain the physical strength for a long time, so that the tolerance of organisms can be improved; meanwhile, the nutritional components can provide nutrition for the organism and supplement a large amount of energy consumed by exercise; more obviously, the baicalin composition can improve the activity of lipoprotein enzyme, rapidly discharge products and toxins in the organism, increase the fat metabolism rate and ensure the metabolic balance of the organism in motion.
Claims (10)
1. The baicalin composition for improving the endurance is characterized by comprising the following main materials in parts by mass:
80 to 780 parts of ginseng, 1 to 25 parts of vitamin B1, 1 to 25 parts of vitamin B2, 3 to 750 parts of L-carnitine, 20 to 860 parts of taurine, 5 to 300 parts of baicalin, 24 to 1600 parts of curculigo rhizome, 10 to 600 parts of sodium chloride, 10 to 600 parts of potassium chloride and 2 to 450 parts of magnesium oxide.
2. The endurance-improving baicalin composition according to claim 1, wherein the endurance-improving baicalin composition comprises the following main materials in parts by mass:
150 to 500 parts of ginseng, 1 to 10 parts of vitamin B1, 1 to 10 parts of vitamin B2, 10 to 500 parts of L-carnitine, 50 to 450 parts of taurine, 10 to 200 parts of baicalin, 80 to 900 parts of curculigo rhizome, 90 to 400 parts of sodium chloride, 90 to 400 parts of potassium chloride and 6 to 150 parts of magnesium oxide.
3. The endurance-improving baicalin composition according to claim 2, wherein the endurance-improving baicalin composition comprises the following main materials in parts by mass:
200 parts of ginseng, 1 part of vitamin B1, 1 part of vitamin B2, 100 parts of L-carnitine, 240 parts of taurine, 50 parts of baicalin, 500 parts of curculigo rhizome, 200 parts of sodium chloride, 200 parts of potassium chloride and 30 parts of magnesium oxide.
4. A endurance-enhancing baicalin composition as claimed in any one of claims 1 to 3, wherein the endurance-enhancing baicalin composition further comprises an adjuvant comprising erythritol and hypromellose; the mass parts of erythritol and hypromellose are respectively 70-700 parts and 10-400 parts.
5. The composition of claim 4, wherein the erythritol and hypromellose are 200 to 400 parts by mass and 50 to 200 parts by mass, respectively.
6. The process for preparing a baicalin composition for improving endurance according to claim 5, wherein the process comprises the steps of:
1) Preparing corresponding raw materials according to the parts by mass;
2) Pulverizing the ginseng of step 1) into particles, and extracting, concentrating, drying and grinding to obtain ginseng extract;
3) Sequentially adding vitamin B1, vitamin B2, L-carnitine, taurine, baicalin, rhizoma Curculiginis, sodium chloride, potassium chloride, magnesium oxide, erythritol and hypromellose into the Ginseng radix extract in step 2), and mixing to obtain baicalin composition preparation.
7. The preparation process according to claim 6, wherein the extraction in step 2) is: adding water into crushed ginseng particles, and decocting for 1 to 3 times at the temperature of between 95 and 110 ℃ for 0.5 to 3 hours each time; the mass of the added water is 5-12 times of that of the ginseng.
8. The preparation process according to claim 7, wherein the first water addition is 12 times the ginseng mass when the decoction is performed 3 times, and the decoction is performed for 3 hours; the mass of water added for the second time is 9 times of that of ginseng, and the ginseng is decocted for 2 hours; the third time of adding water is 5 times of the ginseng, and the mixture is decocted for 1 hour.
9. The process according to claim 6, wherein in step 2), the conditions for concentration are: 40-60 ℃; the drying conditions were: the temperature is 60-90 ℃ and the time is less than or equal to 12 hours.
10. The process of claim 6, wherein in step 3), the candy is in the form of a tablet or pellet.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202311835919.8A CN117581990A (en) | 2023-12-28 | 2023-12-28 | Baicalin composition for improving endurance and preparation process thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202311835919.8A CN117581990A (en) | 2023-12-28 | 2023-12-28 | Baicalin composition for improving endurance and preparation process thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN117581990A true CN117581990A (en) | 2024-02-23 |
Family
ID=89915282
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202311835919.8A Pending CN117581990A (en) | 2023-12-28 | 2023-12-28 | Baicalin composition for improving endurance and preparation process thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN117581990A (en) |
-
2023
- 2023-12-28 CN CN202311835919.8A patent/CN117581990A/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN1625406A (en) | Formulation containing (lyso-) phosphatidylserine for the prevention and treatment of stress states in warm-blooded animals | |
| CN107691952A (en) | A kind of resisting kinetic fatigue, the composition for promoting postexercise recovery and preparation method thereof | |
| KR101343819B1 (en) | The composition for improving antistress, antihyperlipidemia and antiobesity control using red ginseng extract powder, vitamins and minerals, and the health functional food | |
| CN112869162A (en) | Composition with functions of resisting fatigue and improving sleep and preparation method thereof | |
| CN107455625A (en) | A kind of nutrient for plants beverage and its preparation technology with antifatigue weight losing function | |
| CN105770420A (en) | Chinese herbal medicine with anti-cancer effect and preparation method thereof | |
| CN108813501A (en) | With the relieving cough and reducing sputum health honey paste relievingd asthma and adjust function of human body of clearing heat and moistening lung | |
| CN110772564A (en) | Traditional Chinese medicine extract composition with depression mood regulating effect, preparation method thereof and traditional Chinese medicine preparation | |
| CN103735621B (en) | A kind of Chinese medicine composition with blood fat reducing and enhancing immunity effect | |
| CN100350954C (en) | Chinese medicine preparation for promoting lead-removal and its preparation process | |
| CN109157548B (en) | Composition with functions of resisting fatigue and tonifying yang and preparation method thereof | |
| CN105582038A (en) | Composition containing ginseng and Maca ingredients | |
| CN117581990A (en) | Baicalin composition for improving endurance and preparation process thereof | |
| CN114794478A (en) | Composition capable of reducing blood pressure, blood fat and blood sugar and application thereof | |
| CN107788515A (en) | A kind of desertliving cistanche nutritive composition and preparation method thereof | |
| CN107439866A (en) | Matrimony vine chickpea plant nutrients beverage and its preparation technology | |
| CN107441332A (en) | The ginseng composition and preparation method of auxiliary adjustment endocrine metabolism and anti-cancer and cancer-preventing | |
| CN113632979A (en) | Four-season health-preserving beverage for men and women and preparation method thereof | |
| CN101143203B (en) | Compound oral liquid with liver-protecting and stomach-nourishing function | |
| CN103720808B (en) | A kind of composition and use thereof, preparation method with relieving constipation effect | |
| CN113209217A (en) | Traditional Chinese medicine composition for resisting physical fatigue and preparation method thereof | |
| CN108904596B (en) | Composition with memory improving effect | |
| CN102793767B (en) | Radix notoginseng pharmaceutical composition for treating insomnia as well as preparation method and application of pharmaceutical composition | |
| CN105995980A (en) | Composition with weight management function and preparation method thereof | |
| CN112007092A (en) | Anti-alcohol composition and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination |